ATROVENT Drug Patent Profile
✉ Email this page to a colleague
When do Atrovent patents expire, and when can generic versions of Atrovent launch?
Atrovent is a drug marketed by Boehringer Ingelheim and is included in five NDAs. There is one patent protecting this drug.
The generic ingredient in ATROVENT is ipratropium bromide. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atrovent
A generic version of ATROVENT was approved as ipratropium bromide by RITEDOSE CORP on January 26th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATROVENT?
- What are the global sales for ATROVENT?
- What is Average Wholesale Price for ATROVENT?
Summary for ATROVENT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 69 |
Clinical Trials: | 47 |
Patent Applications: | 4,083 |
Drug Prices: | Drug price information for ATROVENT |
What excipients (inactive ingredients) are in ATROVENT? | ATROVENT excipients list |
DailyMed Link: | ATROVENT at DailyMed |
Recent Clinical Trials for ATROVENT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hat Yai Medical Education Center | Phase 3 |
Ohio State University | Phase 4 |
Nationwide Children's Hospital | Phase 4 |
US Patents and Regulatory Information for ATROVENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | ATROVENT | ipratropium bromide | AEROSOL, METERED;INHALATION | 019085-001 | Dec 29, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Boehringer Ingelheim | ATROVENT | ipratropium bromide | SPRAY, METERED;NASAL | 020394-001 | Oct 20, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Boehringer Ingelheim | ATROVENT | ipratropium bromide | SOLUTION;INHALATION | 020228-001 | Sep 29, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Boehringer Ingelheim | ATROVENT | ipratropium bromide | SPRAY, METERED;NASAL | 020393-001 | Oct 20, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATROVENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | ATROVENT | ipratropium bromide | AEROSOL, METERED;INHALATION | 019085-001 | Dec 29, 1986 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | ATROVENT | ipratropium bromide | SPRAY, METERED;NASAL | 020394-001 | Oct 20, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | ATROVENT | ipratropium bromide | SPRAY, METERED;NASAL | 020393-001 | Oct 20, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ATROVENT
See the table below for patents covering ATROVENT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 35841 | ⤷ Sign Up | |
South Africa | 7008400 | ⤷ Sign Up | |
Australia | 4865079 | ⤷ Sign Up | |
Netherlands | 7018033 | ⤷ Sign Up | |
Italy | 7949417 | ⤷ Sign Up | |
Ireland | 34806 | PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |